European Commission approves Johnson & Johnson’s TECVAYLI®▼ (teclistamab) monotherapy for relapsed/refractory multiple myeloma, expanding treatment options from first relapse
Approval is based on Phase 3 results demonstrating signific…
#Europe #EU #EuropeanCommission #(teclistamab) #Approves #Commission #European #expanding #first #for #from #Johnson #Johnson’s #monotherapy #multiple #Myeloma #options #relapse #relapsed/refractory #TECVAYLI®▼ #treatment
https://www.europesays.com/europe/165439/